The views expressed by contributors are their own and not the view of The Hill
The risk of blindness from GLP-1 drugs is too serious to ignore
by Sreedhar Potarazu, opinion contributor - 11/12/26 10:30 AM ET
by Sreedhar Potarazu, opinion contributor - 11/12/26 10:30 AM ET
NOW PLAYING
The popularity of GLP-1 medications has transformed the treatment of obesity and diabetes. Drugs such as Ozempic, Wegovy, Mounjaro and Zepbound have offered millions of people a new approach to managing obesity.
There is, however, a risk of blindness with these drugs that is everyone using them must be aware of.
This week, the Food and Drug Administration finally required manufacturers of GLP-1 medications to include warnings about a potentially serious eye condition called non-arteritic anterior ischemic optic neuropathy. Europe recognized the warning before the U.S. did.…